Dafo Pharmaceutical

Shenzhen Dafo Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Dafo Pharmaceutical") is a Sino-foreign joint venture established in 1994 with a registered capital of 30 million yuan. In November 1999, China Baoan Group increased its capital and expanded its shares, and the registered capital increased to 51 million RMB. In 2015, the company underwent a shareholding system reform, and the registered capital increased to 64 million yuan. In May 2016, the company was successfully listed on the New Third Board, with the securities abbreviation: Dafo Pharmaceutical, and the securities code: 836649. The company is located in the Shenzhen Biomedical Innovation Industrial Park and is one of the few domestic manufacturers focusing on sprays and inhalation preparations, possessing advanced production and testing equipment, a mature technical process system, and a comprehensive quality management system. The company has a subsidiary, Shenzhen Dafo Pharmaceutical Trading Co., Ltd. (hereinafter referred to as "Dafo Pharmaceutical Trading"), which focuses on marketing and agency, and has formed partnerships with pharmaceutical companies in multiple countries. The company has a professional marketing team and has set up offices in more than 20 provinces and cities, forming a nationwide efficient sales network. Dafo Pharmaceutical Trading has drug and medical device business qualifications and operates in coordination with Dafo Pharmaceutical as an integrated industry and trade entity, which is conducive to enhancing the company's overall competitiveness. The company holds production and operation qualifications such as a Drug Production License, Drug Business License, Medical Device Business License, Drug GMP Certificate, Drug GSP Certificate, as well as 8 drug registration approvals and 2 medical device registration certificates. The company's products have good qualification conditions, mostly exclusively produced, many are the first generic drugs in China, and multiple products have obtained Shenzhen Science and Technology Research Achievement Registration Certificates. One product of the company is listed in the National Essential Medicines List, one product is listed in the National Low-Priced Medicines List, and three products are listed in the National Medical Insurance Catalog. The company owns one patent application right and has four products under research. For more than 20 years, the company has been focusing on the domestic otolaryngology and respiratory system market, committed to becoming a specialized, one-stop health solution provider for otolaryngology and respiratory systems, surrounding consultation, diagnosis, treatment, and nursing, throughout pre-diagnosis, diagnosis, and post-diagnosis, conducting health management, formulating solutions, and providing serialized products and integrated services. The company implements a sales model of "prescription-retail interaction, direct sales and recruitment coexistence", adopting a combination of direct sales and recruitment, and expanding the prescription market and retail market through divisions. Currently, the company has hundreds of sales-type customers at all levels and has established strategic cooperative alliances with well-known enterprises focusing on the primary medical market, mid-to-high-end medical market, and retail market; there are nearly a hundred commercial distribution-type customers, all of which are mainstream commercial enterprises in various regions. At present, the company's products cover more than 2,000 hospitals in the prescription market and more than 15,000 pharmacies in the retail market. The company adheres to a market promotion model combining academic marketing and brand marketing, adopting diversified strategies and tools for academic and brand promotion, and has a high brand awareness in the otolaryngology and respiratory system market. In response to the new healthcare reform and the Internet+ trend, the company has launched a pharmaceutical Internet+ strategic layout, initiated the establishment of Shenzhen Yiyao Yijia Pharmaceutical E-commerce Co., Ltd., integrated various resources, innovated business models, and built the "Pharmaceutical e-Home" Internet specialty new and special drug service platform. On the basis of online and offline academic promotion, using mobile Internet technology, it realizes online sales, enhances customer stickiness through professional service marketing, and uses big data to achieve precision marketing, committed to transforming and upgrading into a specialty new and special drug Internet platform service provider, effectively expanding subsequent development space. p Corporate Name: "Dafo" means boundless love, Buddha blesses health. p Corporate Logo: Two hands offering a heart. p Corporate Purpose: Serving public health. p Corporate Vision: Domestic otolaryngology expert and market leader. p Business Philosophy: Professionalism, Value, Growth. p Management Philosophy: Standardization, Innovation, Learning, Execution.